Charlie Schliebs’ in-depth experience as a dealmaker in the life sciences and healthcare field provides iNetworks a unique advantage in understanding biomedical ventures.

From 1988 through 1999, prior to co-founding iNetworks, Mr. Schliebs was a partner in Jones, Day, Reavis & Pogue, a 2,200-lawyer, international law firm. At Jones Day, he was the entrepreneurial founder of the highly successful Pittsburgh office in 1989. Mr. Schliebs formed the Life Sciences Practice Group at Jones Day, and was its worldwide head until he left the firm to co-found iNetworks in late 1999.

While at Jones Day, Mr. Schliebs was the lawyer responsible for all client service to Bayer AG, the international pharmaceutical and chemical conglomerate, for which Mr. Schliebs acted not only as counsel but also as a trusted senior business advisor and dealmaker, making biotechnology investments on behalf of Bayer Pharmaceuticals North American headquarters in West Haven, CT and its Berkeley, California based Biotechnology Unit. Investments were made in such companies as Myriad Genetics, Pharmacopeia, Onyx Pharmaceuticals and Immune Response Corporation. In addition, Mr. Schliebs performed similar roles for biotechnology investments and other projects in other Bayer Divisions, such as Diagnostics, Agriculture and Animal Health. For Bayer and other companies, Mr. Schliebs regularly led the negotiation of research and collaboration agreements, product co-development agreements, co-promotion and co-marketing agreements, and license agreements.

As head of the Jones Day Life Sciences Practice Group, Mr. Schliebs was a regular speaker on topics in the biotechnology and pharmaceutical industries, as well as on bioethics issues. He was an active member of both the Biotechnology Industry Organization, serving on its Business Development and Bioethics Committees as well as the Pre-Emerging Company Committee of its Council of Biotechnology Centers, and the Pennsylvania Biotechnology Association, serving as Co-Chair of its 1999 Annual Meeting, Symposium and BioPartnering Forum held in Philadelphia. He also served as sponsor Co-Chair of the BioPartnering Asia ’99 Conference held in Tokyo.

Prior to joining Jones Day, Mr. Schliebs served in a variety of executive positions at NYSE companies such as Hospital Corporation of America (“HCA”), where he co-founded HCA Venture Capital, the company’s in-house venture arm, investing in emerging healthcare companies. In addition, he was a partner in a large regional law firm in his hometown of Kansas City, Missouri, now Blackwell Sanders Peper Martin LLP.

Mr. Schliebs was an Elliot E. Cheatham Scholar in Law (receiving a full, merit-based scholarship award) at Vanderbilt University School of Law and also holds undergraduate degrees from the University of Pennsylvania, a B.A. and a B.S. Econ. from the Wharton School, where he was a PFAC Scholar, attending Wharton on a merit scholarship for children of steamfitters.